Navigation Links
Immunodeficiency in Biological Technology

GeoVax Labs, Inc. Provides Clinical Studies Update

... will recall that trials conducted using a simian immunodeficiency virus (SIV) prototype of the GeoVax HIV vaccine ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois

... vaccines for diseases caused by the HIV-1 (Human immunodeficiency Virus), and other infectious agents, announced ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results

... on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Update Provided at the BIO CEO & Investor Conference 2009

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, today ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax to Present at the BIO CEO & Investor Conference 2009

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Labs, Inc. Information To Be Available Through Standard & Poor's Market Access Program

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update

... study on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients

... patients with primary immunodeficiency. Primary immunodeficiency is a group of genetic disorders in which the ... improving the diagnosis and treatment of primary immunodeficiency diseases through research, education and ... the only abnormality of concern. About Primary immunodeficiency Disorders ...

GeoVax Labs, Inc. Announces Resignation of Director

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance

... an antiretroviral therapy. About HIV and AIDS HIV, or the human immunodeficiency virus, is a retrovirus that infects cells of the human immune system, ... West Africa. The most advanced stage of HIV infection is AIDS, or acquired immunodeficiency syndrome. HIV can take up to 15 years to develop into AIDS, a process that ...

GeoVax Labs, Inc. Announces First Quarter Financial Results

... focused on developing human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's HIV/AIDS vaccine technology ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

GeoVax Presents Data at AIDS Vaccine 2008 Conference

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

Researchers decode viral process that prepares cells for HIV infection

... the medical community is one step closer to understanding how the human immunodeficiency virus (HIV) attacks cells in the immune system. AIDS, which is caused by ... by the virus. HIV-1 infection causes CD4 T-cell depletion that leads to immunodeficiency and AIDS. During the six-year study, a team largely comprised of ...

Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program

... of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close ...

Mymetics Corporation Important Shareholders Information Conference Call

... of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close ...

Pharmasset Appoints Michael Rogers as Chief Development Officer

... responsible for antiviral discovery activities directed toward human immunodeficiency virus (HIV) and hepatitis C virus (HCV) indications. Dr. Rogers has over ... treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. ...

U.S. Government Awards $15 Million Grant to GeoVax Labs' HIV/AIDS Vaccine Program

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ... GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating ...

FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox

... to smallpox. ACAM2000 is contraindicated for individuals with severe immunodeficiency who are not expected to benefit from the vaccine. These individuals may ... undergoing bone marrow transplantation or persons with primary or acquired immunodeficiency states who require isolation. - The most serious adverse events ...

GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update

... HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS) caused by the virus known as HIV-1 by vaccinating ... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ...

Pharmasset to Present at Canaccord Adams Conference

... of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the ...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

... of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for ...

LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record

... its pDNA and rVSV platforms via a unique prime boost strategy to enhance immune response. Profectus' broad product pipeline will address Human immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papilloma Virus (HPV) and Herpes Simplex Virus (HSV). The Profectus portfolio has received over ...

Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates

... particles from the human circulatory system. The device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats. The Hemopurifier(R) also holds ...

Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results

... completed a phase I/II proof-of-concept study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human immunodeficiency virus (HIV) in September 2008. In February 2009, the company announced that it had licensed its NNRTI program, including IDX899, to GlaxoSmithKline ...

Pharmasset Reports Fiscal First Quarter 2009 Financial Results

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling ...

Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS

... and destruction leaving them able fight opportunistic infections and HIV itself. About HIV/AIDS and CCR5 HIV stands for Human immunodeficiency Virus. HIV infection kills or impairs cells of the immune system progressively destroying the body's ability to fight infections and certain cancers ...

Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Forward-Looking Statements Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: ...

Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling ...

Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients

... KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze(TM) Technology) for the treatment of primary immunodeficiency (PID). The purpose of this clinical trial is to evaluate the safety and efficacy and gain regulatory approval for the treatment of PID using ...

Pharmasset to Present at Two Upcoming Investor Conferences

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic

... could be produced in quantities required for the translation of this program into the clinic. About HIV/AIDS and CCR5 HIV stands for Human immunodeficiency Virus. HIV infection kills or impairs cells of the immune system, progressively destroying the body's ability to fight infections and certain cancers ...

Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines

... in early 2005 to develop and commercialize technologies to reduce the morbidity and mortality caused by human viral diseases, including the human immunodeficiency virus (HIV), the causative agent of AIDS. Founded to fulfill the mission of its co-founders Drs. Gallo, Blattner, and Redfield (collectively, the ...

Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV

... (NASDQ: ROSG) announced today a collaboration with the National Institute of Health to identify microRNAs involved in the progression of the Human immunodeficiency Virus (HIV), that may be used as potential drug targets. Rosetta Genomics has access to the majority of known human and viral microRNAs. From this ...
Other Contents
(Date:8/26/2014)... of mathematical sciences at New Jersey Institute of Technology ... biological clock that sets the pace for daily life. ... all other mammals with fundamental rhythms of life that ... day and with seasonal change. The brain,s circadian clock ... behavior which, when disrupted by experiences such as jet ...
(Date:8/26/2014)... is pumping far more pollution into the atmosphere than ... the National Center for Atmospheric Research estimates that more ... in such fires, emitting gases and particles that can ... new study provides the first rough estimates, on a ... and mercury that are emitted by the fires. Such ...
(Date:8/26/2014)... suggests the planet can produce much more land-plant biomass ... grains and other terrestrial plant parts than previously ... Environmental Science and Technology , recalculates the theoretical limit ... much higher than many current estimates allow. , "When ... you have to make some simplifying assumptions," said University ...
Breaking Biology News(10 mins):Researching fundamental rhythms of life 2Researching fundamental rhythms of life 3Trash burning worldwide significantly worsens air pollution 2Trash burning worldwide significantly worsens air pollution 3Study: Earth can sustain more terrestrial plant growth than previously thought 2Study: Earth can sustain more terrestrial plant growth than previously thought 3
(Date:8/27/2014)... Casey Diekman, assistant professor of mathematical ... helping to gain greater insight into the biological clock ... has harmonized the behavior of humans and all other ... cycle of light and dark experienced each day and ... production related to natural patterns of sleep/wake behavior which, ...
(Date:8/27/2014)... Time to Play Golf, a fast-growing golf social ... With 80-degree temperatures and only partially clouded skies, the day ... Outing. Around 50 golfers showed up to duel it out ... Glen Golf Course in Ringoes, New Jersey. , The outing ... having a great time. Birdies were dropping and those birdies ...
(Date:8/27/2014)... President Obama is considering Executive action soon ... House initiative that supplies green cards and work - ... open a pathway to Social Security benefits, warns ... work authorization would add new long-term liabilities to Social ... target of proposals to cut the growth in beneficiaries’ ...
(Date:8/27/2014)... 27, 2014 The use of ESAs ... life and may eliminate the need for blood transfusion ... recent AllMed webinar, Dr. Zanhua Yi, board certified in ... determining medical necessity of erythropoiesis-stimulating agents (ESAs) in the ... The U.S. Food and Drug Administration (FDA) has approved ...
(Date:8/27/2014)... August 27, 2014 Michael A. ... 2015 edition of The Best Lawyers In America© for ... and "Personal Injury Litigation - Plaintiffs." , Bottar received ... summa cum laude graduate of Syracuse University College of ... the "Civil Practice" chapter of the Syracuse Law Review ...
Breaking Medicine News(10 mins):Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 2Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 3Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 4Health News:Recap: Time To Play Golf Inaugural Golf Outing 2Health News:The Senior Citizens League (TSCL) Warns: White House Action On Immigration Could Give Social Security To Known Illegals 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 3Health News:Michael A. Bottar Selected For Inclusion In The Best Lawyers In America© 2015 2
Other TagsOther Tags